StockWireNews
Could This Tiny Biotech Company Be Ready To Make A Statement In A Specific, Fast-Growing Treatment Market?
Full Report Arrives 7:00PM EST Today
Sign Up To My SMS Update System - Directions Below
January 11th
Greetings Readers,
Mental disorders are an urgent health crisis worldwide, especially exacerbated by the pandemic in recent years.
As per a study by Harvard, the medical cost of mental health conditions is estimated to rise to $6Tn by 2030.
With this rise, doctors/scientists/companies are looking for novel new approaches to combat these issues.
One treatment that has been gaining steam in recent years is the use of psych-e-delics.
The psych-e-delic drugs market is expected to grow at a robust rate and reach a value of $6.33Bn in 2026 from $3.21Bn in 2021 as there is a large unmet need for treatment driving this adoption.
In December 2020, the World Health Organization (WHO) stated that 264 million people suffer from depression.
Growing evidence has suggested that psych-e-delic drugs could treat depression effectively. In a study published in The New England Journal of Medicine, researchers conducted a randomized trial on psi-lo-cybin and found that it is almost as good - if not more effective - than the current antidepressants.
At the end of the six-week trial, all but one of the participants reported a marked improvement in their depressive symptoms - a positive development indeed.
North America is predicted to remain the largest region in the psych-e-delic drugs market due to a surge of clinical trials, massive in-vest-ments, regulatory support, and widespread public awareness.
For those reasons, I've been eyeballing small biotech companies who display tremendous upside potential in taking this fast-growing market to task.
At 7:00PM EST today, you'll get the full report on a company that's just so looking to do that.
To give you something to chew on ahead of time, I've compiled a list of 3 potential catalysts that could fuel this profile to a vertical jump near term.
Key Details Now - 3 Potential Breakout Catalysts For Your New Biotech Profile
#1. New listing news and DTC eligibility could draw serious attention to this tiny company flying under Wall Street's radar.
#2. January news. A major announcement was just made by this company that could have game-changing ramifications for this profile in 2022 and beyond.
#3. With fewer than 40Mn shares in its float, the potential for volatility could appear at a moment's notice.
Since you've got a little time now, do this:
